Nouscom Announces Initial Results from Phase 1 Trial for NOUS-209, an Off-The-Shelf Neoantigen Cancer Vaccine, in MSI-H Solid Tumors

News
2021
2020
Archive

September 16, 2021

Nouscom Announces Initial Results from Phase 1 Trial for NOUS-209, an Off-The-Shelf Neoantigen Cancer Vaccine, in MSI-H Solid Tumors
September 15, 2021

Kinaset Therapeutics Announces Dosing Underway in its Phase 1b Study of KN-002 in Healthy Volunteers and Asthma Patients
September 15, 2021

Scientist.com Announces Acquisition of InsideScientific, a Life Science Webinar, Virtual Event and Content Creation Company
September 9, 2021

RareCyte® Secures $24M Financing to Advance the Orion™ Spatial Biology Platform and Expand Global Commercial Channels
September 9, 2021

Pear and Thimble Point Announce Nominees to Board of Directors
September 9, 2021

VOR33 Granted U.S. FDA Fast Track Designation for AML
September 3, 2021

Impel NeuroPharma Announces U.S. FDA Approval of TRUDHESA™ (Dihydroergotamine Mesylate) Nasal Spray for the Acute Treatment of Migraine
August 26, 2021

Neurogastrx Secures $60 Million in Series B Financing and Expands Management Team to Advance Its Pipeline of Transformative Investigational Therapies for Gastrointestinal Disorders
August 24, 2021

Nouscom Announces First Patient Dosed in a Phase 1B Trial with NOUS-PEV, a Novel Personalized Cancer Immunotherapy, in Advanced Melanoma or Lung Cancer
August 2, 2021

Rallybio Corporation Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

1
2
3
…
12
Next Page »

© 2021 5AM Venture Management LLC